Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alkermes plc chart...

About the Company

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

CEO

Richard F. Pops

Exchange

NASDAQ

Website

alkermes.com

$1B

Total Revenue

2K

Employees

$5B

Market Capitalization

17.73

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALKS News

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)

5h ago, source: Yahoo Finance

Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovative medicines that address ...

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

11d ago, source: Yahoo Finance

DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent ...

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Sandy, you may begin. Thank you, Rob. Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter and year ended December 31 ...

Alkermes PLC

7d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alkermes: Q4 Earnings Snapshot

1mon ago, source: Houston Chronicle

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported fourth-quarter net income of $112.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...

Alkermes Announces Interim Financial Leadership Appointments

1mon ago, source: Hosted on MSN

Alkermes plc has appointed Blair C. Jackson as interim principal financial officer and Samuel J. Parisi as interim principal accounting officer during Iain M. Brown’s medical leave. Jackson ...

Alkermes plc Q4 Earnings Summary

1mon ago, source: Nasdaq

(RTTNews) - Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $112.78 million in Q4 vs. -$28.25 million in the same period last year. EPS: $0.66 in Q4 vs. -$0.17 in the same ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...